Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Solutions to Reduce Unnecessary Imaging-Reply.

Oren O, Kebebew E, Ioannidis JPA.

JAMA. 2019 Jun 11;321(22):2243. doi: 10.1001/jama.2019.4021. No abstract available.

PMID:
31184737
2.

MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.

Ruff SM, Ayabe RI, Malekzadeh P, Good ML, Wach MM, Gonzales MK, Tirosh A, Nilubol N, Pacak K, Kebebew E, Patel D.

J Surg Res. 2019 May 27;243:1-7. doi: 10.1016/j.jss.2019.04.086. [Epub ahead of print]

PMID:
31146085
3.

Family Medicine Residents' Attitudes About Training in Ethiopia and the United States.

Gossa W, Jones C, Raiculescu S, Melaku M, Kebebew E, Zerihun M, Fetters MD.

Fam Med. 2019 May;51(5):424-429. doi: 10.22454/FamMed.2019.190022.

4.

Reply: Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

El Lakis M, Kebebew E.

Surgery. 2019 Jun;165(6):1246-1247. doi: 10.1016/j.surg.2019.02.003. Epub 2019 Mar 23. No abstract available.

PMID:
30910232
5.

ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.

Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, Neychev V, Stevenson H, Keutgen XM, Patel D, Nilubol N, Meltzer P, Kebebew E.

Endocr Pract. 2019 Jun;25(6):580-588. doi: 10.4158/EP-2018-0603. Epub 2019 Mar 13.

PMID:
30865533
6.

Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific.

Green P, Kebebew E.

Am J Surg. 2019 Jul;218(1):14-17. doi: 10.1016/j.amjsurg.2019.02.019. Epub 2019 Feb 14.

PMID:
30862353
7.

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma.

Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, Gonzales MK, Viana B, Alrezk R, Adams KT, Tena I, Chen A, Neuzil J, Raygada M, Kebebew E, Taieb D, O'Dorisio MS, O'Dorisio T, Civelek AC, Stratakis CA, Mercado-Asis L, Pacak K.

Front Oncol. 2019 Feb 22;9:53. doi: 10.3389/fonc.2019.00053. eCollection 2019.

8.

The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors.

Shell J, Tirosh A, Millo C, Sadowski SM, Assadipour Y, Green P, Patel D, Nilubol N, Kebebew E.

Eur J Radiol. 2019 Mar;112:130-135. doi: 10.1016/j.ejrad.2018.11.023. Epub 2018 Nov 22.

PMID:
30777201
9.

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.

Klubo-Gwiezdzinska J, Auh S, Gershengorn M, Daley B, Bikas A, Burman K, Wartofsky L, Urken M, Dewey E, Smallridge R, Chindris AM, Kebebew E.

JAMA Netw Open. 2019 Feb 1;2(2):e187754. doi: 10.1001/jamanetworkopen.2018.7754.

10.

Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.

Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM.

Thyroid. 2019 Apr;29(4):530-539. doi: 10.1089/thy.2018.0687. Epub 2019 Feb 13.

PMID:
30654714
11.

Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.

Tirosh A, Mukherjee S, Lack J, Gara SK, Wang S, Quezado MM, Keutgen XM, Wu X, Cam M, Kumar S, Patel D, Nilubol N, Tyagi MV, Kebebew E.

Cancer. 2019 Apr 15;125(8):1247-1257. doi: 10.1002/cncr.31930. Epub 2019 Jan 8.

PMID:
30620390
12.

Curbing Unnecessary and Wasted Diagnostic Imaging.

Oren O, Kebebew E, Ioannidis JPA.

JAMA. 2019 Jan 22;321(3):245-246. doi: 10.1001/jama.2018.20295. No abstract available.

PMID:
30615023
13.

High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy.

Green P, Zagzag J, Patel D, Weinstein LS, Simonds WF, Blau J, Marx S, Kebebew E, Perrier N, Nilubol N.

Surgery. 2019 Jan;165(1):124-128. doi: 10.1016/j.surg.2018.04.064. Epub 2018 Nov 7.

PMID:
30414705
14.

Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Boufraqech M, Patel D, Nilubol N, Powers A, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin J, Knauf J, Parangi S, Venzon D, Quezado M, Kebebew E.

Thyroid. 2019 Jan;29(1):79-92. doi: 10.1089/thy.2018.0424. Epub 2018 Dec 28.

PMID:
30398411
15.

ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors.

Gaitanidis A, Patel D, Kebebew E.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):874-875. doi: 10.1245/s10434-018-6948-x. Epub 2018 Oct 23. No abstract available.

PMID:
30353397
16.

Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

El Lakis M, Giannakou A, Nockel PJ, Wiseman D, Gara SK, Patel D, Sater ZA, Kushchayeva YY, Klubo-Gwiezdzinska J, Nilubol N, Merino MJ, Kebebew E.

Surgery. 2019 Jan;165(1):50-57. doi: 10.1016/j.surg.2018.05.075. Epub 2018 Oct 14.

PMID:
30327187
17.

Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E.

Semin Oncol. 2018 Aug;45(4):232-235. doi: 10.1053/j.seminoncol.2018.07.002. Epub 2018 Oct 11. Review.

PMID:
30318110
18.

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.

Gara SK, Lack J, Zhang L, Harris E, Cam M, Kebebew E.

Nat Commun. 2018 Oct 9;9(1):4172. doi: 10.1038/s41467-018-06366-z.

19.

Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors.

Tirosh A, Journy N, Folio LR, Lee C, Leite C, Yao J, Kovacs W, Linehan WM, Malayeri A, Kebebew E, Berrington de González A.

Radiology. 2019 Jan;290(1):116-124. doi: 10.1148/radiol.2018180687. Epub 2018 Oct 9.

PMID:
30299237
20.

Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors.

El Lakis M, Gianakou A, Nockel P, Wiseman D, Tirosh A, Quezado MA, Patel D, Nilubol N, Pacak K, Sadowski SM, Kebebew E.

JAMA Surg. 2019 Jan 1;154(1):40-45. doi: 10.1001/jamasurg.2018.3475.

PMID:
30267071
21.

Aggressive resection of neuroendocrine tumor (NET) liver metastases: NET neutral or gain?

Cisco R, Lin D, Kebebew E.

Surgery. 2019 Jan;165(1):176-177. doi: 10.1016/j.surg.2018.08.019. Epub 2018 Sep 25. No abstract available.

PMID:
30266442
22.

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.

Nilubol N, Boufraqech M, Zhang L, Gaskins K, Shen M, Zhang YQ, Gara SK, Austin CP, Kebebew E.

Oncotarget. 2018 Aug 31;9(68):33030-33042. doi: 10.18632/oncotarget.26050. eCollection 2018 Aug 31.

23.

Neural monitoring in endocrine neck surgery.

El Lakis M, Kebebew E.

Gland Surg. 2018 Aug;7(Suppl 1):S86-S88. doi: 10.21037/gs.2018.03.08. No abstract available.

24.

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.

Shell J, Keutgen XM, Millo C, Nilubol N, Patel D, Sadowski S, Boufraqech M, Yang L, Merkel R, Atallah C, Herscovitch P, Kebebew E.

Int J Endocr Oncol. 2018 Feb 2;5(1):IJE04. doi: 10.2217/ije-2017-0005. eCollection 2018 Feb.

25.

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA.

Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.

PMID:
30107176
26.

Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.

Tirosh A, Nilubol N, Patel D, Kebebew E.

Endocr Pract. 2018 Aug;24(8):710-717. doi: 10.4158/EP-2018-0022. Epub 2018 Aug 7.

PMID:
30084688
27.

Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database.

Tella SH, Kommalapati A, Yaturu S, Kebebew E.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3566-3573. doi: 10.1210/jc.2018-00918.

PMID:
29982685
28.

The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.

Luo H, Tobey A, Auh S, Cochran C, Zemskova M, Reynolds J, Lima C, Burman K, Wartofsky L, Skarulis M, Kebebew E, Klubo-Gwiezdzinska J.

Clin Endocrinol (Oxf). 2018 Oct;89(4):481-488. doi: 10.1111/cen.13806. Epub 2018 Aug 13.

PMID:
29972703
29.

Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection.

Nockel P, Tirosh A, El Lakis M, Gaitanidis A, Merkel R, Patel D, Nilubol N, Sadowski SM, Cochran C, Gorden P, Kebebew E.

Endocrine. 2018 Sep;61(3):422-427. doi: 10.1007/s12020-018-1633-1. Epub 2018 Jun 19.

PMID:
29923016
30.

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, Agarwal S, Klubo-Gwiezdzinska J.

Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.

31.

Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism.

Sadowski SM, Pusztaszeri M, Brulhart-Meynet MC, Petrenko V, De Vito C, Sobel J, Delucinge-Vivier C, Kebebew E, Regazzi R, Philippe J, Triponez F, Dibner C.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2189-2198. doi: 10.1210/jc.2017-02506.

PMID:
29659895
32.

Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.

Nilubol N, Yuan Z, Paciotti GF, Tamarkin L, Sanchez C, Gaskins K, Freedman EM, Cao S, Zhao J, Kingston DGI, Libutti SK, Kebebew E.

J Natl Cancer Inst. 2018 Sep 1;110(9):1019-1029. doi: 10.1093/jnci/djy003.

33.

Frequency and consequence of the recurrent YY1 p.T372R mutation in sporadic insulinomas.

Parekh VI, Modali SD, Welch J, Simonds WF, Weinstein LS, Kebebew E, Agarwal SK.

Endocr Relat Cancer. 2018 May;25(5):L31-L35. doi: 10.1530/ERC-17-0311. Epub 2018 Feb 21. No abstract available.

34.

Convolutional Invasion and Expansion Networks for Tumor Growth Prediction.

Zhang L, Lu L, Summers RM, Kebebew E, Yao J.

IEEE Trans Med Imaging. 2018 Feb;37(2):638-648. doi: 10.1109/TMI.2017.2774044.

35.

Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism.

El Lakis M, Nockel P, Gaitanidis A, Guan B, Agarwal S, Welch J, Simonds WF, Weinstein L, Marx S, Nilubol N, Patel D, Merkel R, Tirosh A, Kebebew E.

J Am Coll Surg. 2018 May;226(5):933-938. doi: 10.1016/j.jamcollsurg.2018.01.007. Epub 2018 Mar 2.

36.

Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery.

Nockel P, El Lakis M, Gaitanidis A, Merkel R, Patel D, Nilubol N, Prodanov T, Pacak K, Kebebew E.

Ann Surg. 2019 Apr;269(4):741-747. doi: 10.1097/SLA.0000000000002671.

PMID:
29334561
37.

In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.

Tirosh A, El Lakis M, Green P, Nockel P, Patel D, Nilubol N, Gara SK, Keutgen XM, Linehan WM, Kebebew E.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1631-1638. doi: 10.1210/jc.2017-02434.

38.

Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report.

Shell J, Patel D, Powers A, Quezado M, Killian K, Meltzer P, Zhu J, Gaitanidis A, Karzai F, Neychev V, Green P, Kebebew E.

J Endocr Soc. 2017 Jul 7;1(9):1124-1134. doi: 10.1210/js.2017-00156. eCollection 2017 Sep 1.

39.

Ethnicity of Patients With Germline GCM2-Activating Variants and Primary Hyperparathyroidism.

Guan B, Welch JM, Vemulapalli M, Li Y, Ling H, Kebebew E, Simonds WF, Marx SJ, Agarwal SK.

J Endocr Soc. 2017 Mar 23;1(5):488-499. doi: 10.1210/js.2017-00043. eCollection 2017 May 1.

40.

To the editor.

Kebebew E, Kumar Gara S.

NPJ Genom Med. 2017 Jun 30;2:21. doi: 10.1038/s41525-017-0026-3. eCollection 2017. No abstract available.

41.

Ethnic specific differences in endocrine neoplasms: The role of susceptibility genes.

Kebebew E.

Am J Surg. 2018 Jun;215(6):1060-1061. doi: 10.1016/j.amjsurg.2017.12.005. Epub 2017 Dec 8. Review.

PMID:
29246404
42.

Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population.

Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, Herscovitch P, Adams KT, Taïeb D, Metwalli AR, Linehan WM, Brofferio A, Stratakis CA, Kebebew E, Lodish M, Civelek AC, Pacak K.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):787-797. doi: 10.1007/s00259-017-3896-9. Epub 2017 Dec 4.

PMID:
29204718
43.

Thyroid Cancer: Is It All in the Genes?

Kebebew E.

J Natl Cancer Inst. 2018 Apr 1;110(4):327-328. doi: 10.1093/jnci/djx210. No abstract available.

44.

Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors.

Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E.

Gastroenterology. 2018 Mar;154(4):998-1008.e1. doi: 10.1053/j.gastro.2017.11.008. Epub 2017 Nov 16.

45.

Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.

Keutgen XM, Kumar S, Gara S, Boufraqech M, Agarwal S, Hruban RH, Nilubol N, Quezado M, Finney R, Cam M, Kebebew E.

Cancer. 2018 Feb 1;124(3):636-647. doi: 10.1002/cncr.31057. Epub 2017 Nov 17. Erratum in: Cancer. 2018 Apr 1;124(7):1518.

46.

Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis.

Gaitanidis A, Patel D, Nilubol N, Tirosh A, Sadowski S, Kebebew E.

Ann Surg Oncol. 2018 Jan;25(1):122-130. doi: 10.1245/s10434-017-6241-4. Epub 2017 Nov 13.

PMID:
29134377
47.

Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery.

Nockel P, El Lakis M, Gaitanidis A, Yang L, Merkel R, Patel D, Nilubol N, Prodanov T, Pacak K, Kebebew E.

Surgery. 2018 Jan;163(1):191-196. doi: 10.1016/j.surg.2017.05.025. Epub 2017 Nov 7.

48.

Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure.

El Lakis M, Nockel P, Guan B, Agarwal S, Welch J, Simonds WF, Marx S, Li Y, Nilubol N, Patel D, Yang L, Merkel R, Kebebew E.

Surgery. 2018 Jan;163(1):31-34. doi: 10.1016/j.surg.2017.04.027. Epub 2017 Nov 3.

49.

Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease.

Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E.

JAMA Oncol. 2018 Jan 1;4(1):124-126. doi: 10.1001/jamaoncol.2017.3428. No abstract available.

50.

The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

Tirosh A, Kebebew E.

Future Oncol. 2018 Jan;14(2):111-122. doi: 10.2217/fon-2017-0393. Epub 2017 Oct 26. Review.

Supplemental Content

Loading ...
Support Center